Lincoln Pharma wins patent for NDDS

Ahmedabad-based Lincoln Pharmaceuticals Limited (LPL), has received a patent for a Nasal Drug Delivery System (NDDS) in India that helps in arresting or preventing vomiting and nausea that will particularly help in chemotherapy induced nausea.

Currently, anti-vomiting treatments are available in the conventional form of tablet and injection in the country, and LPL claimed that the nasal delivery system would help reduce the relief time. It is the first company in India to introduce an anti-vomiting treatment in the form of a nasal spray pump.

Speaking on winning the patent for the novel NDDS in India, Mahendra G Patel, managing director, LPL said, "The new nasal pump spray offering takes us closer to providing customers with improved drugs for better treatment. Vomiting and nausea is a common problem which causes patients a great deal of discomfort and weakness. We wanted to provide immediate relief to people suffering from this problem. The product will hit the markets in India in the next two to three months and we plan to market this product internationally as well."

 

Clinical tests on the efficacy and tolerability of the new nasal spray formulation of Ondansetron Hydrochloride (the molecule that serves as an agent that prevents or arrests vomiting) has proven its ability to prevent vomiting and nausea. The Ondansetron Hydrochloride molecule can quickly be transferred across the single epithelial cell layer directly into the blood stream without first-pass hepatic and intestinal metabolism. Positive effects can be reached within five minutes for smaller drug molecules.